Alberto MartÃÂnez-MuÃÂ±oz, Karen Nathalie Geraldo-Bastida, Alondra Nataly Lobatos-Buenrostro, Juan Luis GutiÃÂ©rrez-VelÃÂ¡zquez, Carlos Joel Salas-Montantes, HÃÂ©ctor Manuel GonzÃÂ¡lez-MartÃÂnez, Araceli Guadalupe Medina-Nolasco, Porfirio de la Cruz-Cruz, Sandra Lara-Figueroa, Ricardo Zamora-RamÃÂrez, JosÃÂ© Luis Rubio-Santiago
The nifedipine immediate-release formulation has been associated with reflex sympathetic nervous system activation leading to several adverse effects such as flushing, tachycardia, worsening myocardial ischemia, and cerebrovascular ischemia. Development of a modified-release formulation represents a challenge, particularly the development of a once-daily formulation. Therefore, these studies evaluated the pharmacokinetic profile of a new 30-mg Extended-Release Nifedipine Tablets in Mexican population. The formulation [ANHITEN-A®] was manufactured by Ultra Laboratorios S.A. de C.V. [Jalisco, Mexico] with number of batch 9JN134A and expiration date September 2021.
Published Date: 2021-08-24; Received Date: 2021-08-03